Showing results (131-140 of 182) with videos related to

Sort By:
Pageof 19
Pharmacogenetics and Genomics|July 22, 2009
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomesPenelope A Bradbury, Matthew H Kulke, Rebecca S Heist, et al.
Anticancer Research|February 7, 2016
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine TumoursNicola Fazio, Roberto Buzzoni, Eric Baudin, et al.
The Oncologist|January 21, 2025
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumorsKimberly Perez, Matthew H Kulke, Hui Zheng, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 27, 2021
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATEJonathan R Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, et al.
European Journal of Cancer (Oxford, England : 1990)|May 17, 2023
Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumoursJorge Hernando, Maria Roca-Herrera, Alejandro García-Álvarez, et al.
Pancreas|February 4, 2020
Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine TumorsRachel E Rosenblum, Cynthia K Harris, Kiwoon Joshua Baeg, et al.
Cancer Science|October 22, 2017
Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysisNicola Fazio, Roberto Buzzoni, Gianfranco Delle Fave, et al.
Carcinogenesis|May 25, 2011
Genetic associations with sporadic neuroendocrine tumor riskMonica Ter-Minassian, Zhaoxi Wang, Kofi Asomaning, et al.
Pageof 19